Lundbeck, which will first launch projects related to schizophrenia and Parkinson’s disease, will use clinical data from the Watson Health Cloud to identify new drug therapies. Lundbeck focuses on developing therapeutics related to the underlying biological mechanisms of psychiatric and neurological disorders, rather than their symptoms.
“By combining our expertise in brain research with IBM’s cognitive computer technology, we expect to improve our foundation for this work, so we can develop new and improved treatments for the 425 million people who suffer from the psychiatric and neurological disorders which Lundbeck focuses on,” said Anders Gersel Pedersen, executive vice president of research and development at Lundbeck.
More articles on health IT:
Oklahoma HIE to disband
IBM revenue declines for 19th quarter
TriHealth reports potential release of 1k patients’ information
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
